- Home
- GLOB vs MANE Comparison
GLOB vs MANE Comparison
Compare GLOB & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLOB | MANE |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLOB | MANE |
|---|---|---|
| Price | $46.55 | $58.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $78.64 | $78.33 |
| AVG Volume (30 Days) | ★ 1.1M | 352.6K |
| Earning Date | 05-14-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.06 | N/A |
| Revenue Next Year | $5.30 | N/A |
| P/E Ratio | $22.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.77 | $36.26 |
| 52 Week High | $142.25 | $69.41 |
Technical Indicators
Market Signals| Indicator | GLOB | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 57.81 |
| Support Level | $41.39 | $39.73 |
| Resistance Level | $71.47 | $63.03 |
| Average True Range (ATR) | 2.16 | 5.63 |
| MACD | 0.61 | -0.24 |
| Stochastic Oscillator | 82.44 | 44.85 |
Price Performance
Historical ComparisonAbout GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.